ZNTL
NASDAQZentalis Pharmaceuticals Inc.
News · 26 weeks47+267%
2026-03-012026-08-23
Mix2190d
- Other6(29%)
- Insider6(29%)
- SEC Filings4(19%)
- Offering3(14%)
- Analyst2(10%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Zentalis Pharmaceuticals Inc.SCHEDULE 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
- INSIDERLarge owner Walters Group bought $15,172,500 worth of shares (4,335,000 units at $3.50) (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- PRZentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesSAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL) ("Zentalis" or the "Company"), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced that it has closed its previously announced underwritten public offering of 26,450,000 shares of its common stock, including 3,450,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $3.50 per share. The total gross proceeds to the Compa
- PRZentalis Pharmaceuticals Announces Pricing of Underwritten Public OfferingSAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL) ("Zentalis" or the "Company"), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the pricing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $3.50 per share. The total gross proceeds to the Company from the offering are expected to be approximately $80.5 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. All of the com
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Zentalis Pharmaceuticals Inc.SCHEDULE 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
- SECSEC Form 424B5 filed by Zentalis Pharmaceuticals Inc.424B5 - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- PRZentalis Pharmaceuticals Announces Proposed Underwritten Public OfferingSAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL) ("Zentalis" or the "Company"), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the commencement of a proposed underwritten public offering of shares of its common stock and in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities to be sold in the proposed offering will be sold by the Company. The Company also expects to grant the underwriters a 30
- SECSEC Form 10-Q filed by Zentalis Pharmaceuticals Inc.10-Q - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- SECZentalis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- PRZentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business UpdatesFollowing U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2Enrollment completed in Part 2a and 2b of the DENALI trial; Part 2c is enrollingDENALI Part 2 topline readout expected in 1H 2027 to allow for data maturation post full enrollment$174.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, providing runway into late 2027 to support execution of key milestones SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker
- PRZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on August 3, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 84,000 shares of the Company’s common stock to two (2) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each suc
- ANALYSTRodman & Renshaw initiated coverage on Zentalis Pharma with a new price targetRodman & Renshaw initiated coverage of Zentalis Pharma with a rating of Buy and set a new price target of $11.00
- PRZentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. "We are pleased that the overall survival results from the DENALI Part 1b study are accepted as a rapid oral presentation at ESMO." said Julie Eastland, Chief Exe
- ANALYSTMizuho initiated coverage on Zentalis Pharma with a new price targetMizuho initiated coverage of Zentalis Pharma with a rating of Outperform and set a new price target of $8.00
- INSIDERDirector Johnson David Michael was granted 57,100 shares, increasing direct ownership by 23% to 307,521 units (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERDirector Skvarka Jan was granted 57,100 shares, increasing direct ownership by 28% to 264,254 units (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERDirector Walker Luke Nathaniel was granted 57,100 shares, increasing direct ownership by 40% to 201,384 units (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERDirector Kariuki Enoch was granted 57,100 shares, increasing direct ownership by 42% to 194,465 units (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERDirector Myers Scott Dunseth was granted 57,100 shares, increasing direct ownership by 17% to 395,895 units (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- SECZentalis Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- PRZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on June 1, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 191,000 shares of the Company's common stock to two (2) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such
- INSIDERDirector Campbell Shannon was granted 114,200 shares (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERSEC Form 3 filed by new insider Campbell Shannon3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- SECSEC Form DEFA14A filed by Zentalis Pharmaceuticals Inc.DEFA14A - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- SECZentalis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
ZNTL FAQ
7 questionsWhat does Zentalis Pharmaceuticals Inc. do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as...Where does ZNTL stock trade?
Zentalis Pharmaceuticals Inc. (ZNTL) is listed on NASDAQ.What sector and industry is ZNTL in?
Zentalis Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zentalis Pharmaceuticals Inc. go public?
Zentalis Pharmaceuticals Inc. (ZNTL) completed its IPO in 2020.What are analysts saying about ZNTL?
Zentalis Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $1100.00 price target on 2026-07-23. Recent price targets range from $400.00 to $1100.00.What companies are similar to ZNTL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZNTL side-by-side with any of them on Quantisnow.How can I track ZNTL on Quantisnow?
Quantisnow aggregates Zentalis Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZNTL to receive live email and push alerts on every new disclosure.